טוען...
FGF19 and FGF21: In NASH we trust
OBJECTIVE: FGF19 and FGF21 have shown therapeutic promise since their discovery, attested by the fact there are at least 5 assets that activate the FGFR/KLB pathway and one FGF19 analog in clinical development. METHODS: We performed a detailed analyses of published preclinical and clinical data to o...
שמור ב:
| הוצא לאור ב: | Mol Metab |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Elsevier
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8085573/ https://ncbi.nlm.nih.gov/pubmed/33383173 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molmet.2020.101152 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|